U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07462624) titled 'REpeat Intervention For Failed Surgical BioProsthEtic AorTic Valves (REPEAT)' on Jan. 19.
Brief Summary: The overall hypothesis is that redo aortic valve replacement (rAVR) is superior to valve-invalve transcatheter aortic valve replacement (ViV-TAVR) for the composite endpoint of freedom from all-cause mortality, all-cause stroke, myocardial infarction, and rehospitalization for heart failure or aortic valve re-intervention at 5 years.
Study Start Date: Nov. 10, 2025
Study Type: INTERVENTIONAL
Condition:
Degenerative Aortic Valve Disease
Intervention:
PROCEDURE: Transfemoral transcatheter valve-in-valve implantation
The int...